EGFR and metabolic dysfunction-associated steatotic liver disease: The protein expression of SREBP-1 and its lipogenic targets such as fatty acid synthase (FASN) was increased in HFD-induced NAFLD, whereas inhibiting EGFR decreased SREBP-1 and FASN expression.